Cell-Free DNA Isolation And Extraction Global Market Report 2024

Cell-free DNA (cfDNA) isolation and extraction involves the separation and extraction of nucleic acid molecules, specifically DNA, from biological samples such as blood, plasma, serum, urine, or other bodily fluids where DNA is found outside cells. This process is crucial in molecular biology and medical research, enabling the analysis of genetic material in bodily fluids for diagnostic, prognostic, and therapeutic purposes.

The primary product types for cfDNA isolation and extraction include kits, reagents, and instruments. Reagents are substances or compounds added to a system to induce a chemical reaction or to test if one occurs. Technologies such as column-based isolation, magnetic beads, and silica membranes are employed in various applications such as non-invasive prenatal testing (NIPT), oncology, transplant rejection monitoring, and other medical research applications. These products serve diverse end-users including hospitals, diagnostic laboratories, research institutes, and biotech and pharmaceutical companies.

The cell-free DNA isolation and extraction market research report is one of a series of new reports that provides cell-free DNA isolation and extraction market statistics, including cell-free DNA isolation and extraction industry global market size, regional shares, competitors with a cell-free DNA isolation and extraction market share, detailed cell-free DNA isolation and extraction market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-free DNA isolation and extraction industry. This cell-free DNA isolation and extraction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell-free DNA isolation and extraction market size has grown strongly in recent years. It will grow from $1.81 billion in 2023 to $1.93 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historic period can be attributed to several factors, an increase in the prevalence of cancer, advancements in microbial sequencing technologies, substantial investments by healthcare companies, rising investments in genomics and biotechnology, and increased funding for research and development initiatives.

The cell-free DNA isolation and extraction market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. In the forecast period, growth can be attributed to several factors, increasing adoption of cell-free DNA isolation and extraction kits and tubes, expanding investments in genomics and biotechnology, advancements in molecular diagnostics technology, growing demand for personalized medicine, and rising prevalence of chronic and infectious diseases. Major trends expected during this period include the development of new products tailored to market needs, strategic partnerships and collaborations to leverage expertise and resources, mergers and acquisitions to strengthen market positions, ongoing technological advancements in isolation and extraction techniques, and continuous launches of innovative products.

The cell-free DNA isolation and extraction market is poised for growth driven by the increasing prevalence of cancer. Cancer encompasses a diverse group of diseases characterized by abnormal cell growth, often leading to tumor formation and potential spread to other parts of the body. Factors contributing to the rising cancer incidence include obesity, genetic predispositions, and viral infections such as hepatitis B and C, Epstein-Barr virus (EBV), and human papillomavirus (HPV). Cell-free DNA (cfDNA) isolation and extraction technologies play a crucial role in cancer research and treatment by enabling detailed genomic analysis. These techniques provide insights into tumor biology, treatment responses, and disease progression, potentially transforming cancer management through early detection and personalized therapeutic approaches. For example, the American Society of Clinical Oncology reported approximately 20 million new cancer cases diagnosed in 2022, with projections suggesting this number could rise to 35 million by 2050. Cancer-related deaths are estimated at 9.7 million annually, underscoring the critical need for advanced diagnostic and therapeutic solutions facilitated by cfDNA isolation and extraction technologies.

The cell-free DNA isolation and extraction market is poised for growth driven by the increasing demand for personalized medicine. Personalized medicine tailors healthcare decisions and treatments to individual patients based on their genetic makeup, environmental factors, and lifestyle. This approach is gaining traction due to rising rates of cancer and the prevalence of chronic diseases worldwide. Cell-free DNA isolation and extraction technologies play a pivotal role in personalized medicine by offering a non-invasive and comprehensive method for diagnosing, monitoring, and treating diseases, particularly cancer, based on an individual's unique genetic profile. For instance, the Personalized Medicine Coalition reported that in 2022, 12 new customized medications were approved, accounting for approximately 34% of all newly approved treatments, signaling a significant increase from previous years. This underscores the growing adoption of personalized therapeutic approaches and their impact on driving the demand for advanced genomic analysis tools such as cell-free DNA isolation and extraction.

Leading companies in the cell-free DNA isolation and extraction market are focusing on innovation to maintain a competitive edge. They are developing cutting-edge products such as automated DNA extraction instruments, which are sophisticated laboratory devices designed to streamline and automate the process of isolating DNA from diverse biological samples. Yourgene Health plc, for example, launched the MagBench Automated DNA Extraction Instrument and Kit in September 2023. This innovative solution is tailored to optimize the Sage 32 NIPT workflow in Asia-Pacific and the Middle East, featuring advanced features that enhance the efficiency and precision of DNA extraction from maternal blood samples using magnetic bead-based technology. These advancements in automated DNA extraction instruments are crucial for improving diagnostic accuracy and efficiency in clinical settings, supporting the growing demand for personalized medicine and enhancing patient outcomes through targeted therapies based on genomic insights.

Major companies operating in the cell-free DNA isolation and extraction market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., Promega Corporation, STRATEC Biomedical AG, STRECK Inc., Omega Bio-tek Inc., SeraCare Life Sciences Inc., Yourgene Health plc, System Biosciences LLC, PreAnalytiX GmbH, Bioo Scientific Corporation, BioCAT GmbH, Norgen Biotek Corp., Epigentek Group Inc., NVIGEN Inc.

North America was the largest region in the cell-free DNA isolation and extraction market in 2023. The regions covered in the cell-free DNA isolation and extraction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell-free DNA isolation and extraction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell-free DNA isolation and extraction market consists revenues earned by entities by providing services such as sample collection and stabilization, isolation protocols, and quality control and quantification. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA isolation and extraction market consists of sales of automated extraction systems, high-speed centrifugation machines, magnetic bead separators, polymerase chain reaction (PCR) machines, and microfluidic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.